Literature DB >> 10873563

Downregulation of proapoptotic proteins Bax and Bcl-X(S) in p53 overexpressing hepatocellular carcinomas.

W Beerheide1, Y J Tan, E Teng, A E Ting, A Jedpiyawongse, P Srivatanakul.   

Abstract

As the occurrence of structural p53 mutations in hepatocellular carcinoma (HCC) in Thailand was previously reported to be much lower than that found in other high-incidence HCC areas, we analyzed 16 HCC samples from Thailand to determine the expression and functionality of p53 protein. We observed the overexpression of p53 protein in 69% of HCC, despite the prevalence of the wild-type p53 gene. However, the overexpressed p53 protein was nonfunctional as suggested by its inability to modulate the expressions of several p53 effector proteins (p21 and Bcl-2 family proteins). In addition, we observed significant underexpression of two proapoptotic proteins, Bax and Bcl-X(S), in 81% (P = 0.02) and 64% (P = 0.03) of HCC, respectively. Consequently, the ratios of proapoptotic to antiapoptotic BCL-2 family proteins were reduced in 88% of the HCC tumor tissues when compared to normal tissues, such that the rheostat between BCL-2 family proteins is strongly skewed toward enhanced cell survival in the tumor cells. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873563     DOI: 10.1006/bbrc.2000.2891

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  21 in total

1.  Overexpression of Bax induces apoptosis and enhances drug sensitivity of hepatocellular cancer-9204 cells.

Authors:  Jian-Yong Zheng; Guang-Shun Yang; Wei-Zhong Wang; Jiang Li; Kai-Zong Li; Wen-Xian Guan; Wen-Liang Wang
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

2.  Macrolide antibiotics differentially influence human HepG2 cytotoxicity and modulate intrinsic/extrinsic apoptotic pathways in rat hepatocellular carcinoma model.

Authors:  Nagwa I Abdel-Hamid; Mona F El-Azab; Yasser M Moustafa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-01-09       Impact factor: 3.000

Review 3.  Apoptosis in liver carcinogenesis and chemotherapy.

Authors:  Joaquim Moreno-Càceres; Isabel Fabregat
Journal:  Hepat Oncol       Date:  2015-11-11

4.  Development of the human cancer microRNA network.

Authors:  Sanghamitra Bandyopadhyay; Ramkrishna Mitra; Ujjwal Maulik; Michael Q Zhang
Journal:  Silence       Date:  2010-02-02

5.  A small inhibitor of the interaction between Bax and Bcl-X(L) can synergize with methylprednisolone to induce apoptosis in Bcl-X(L)-overexpressing breast-cancer cells.

Authors:  Yee-Joo Tan; Eileen Teng; Anthony E Ting
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-16       Impact factor: 4.553

6.  Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocellular carcinoma.

Authors:  Cheng-Tang Chiu; Ta-Sen Yeh; Jui-Chen Hsu; Mün-Fu Chen
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

7.  A bibenzyl from Dendrobium ellipsophyllum induces apoptosis in human lung cancer cells.

Authors:  Anirut Hlosrichok; Somruethai Sumkhemthong; Boonchoo Sritularak; Pithi Chanvorachote; Chatchai Chaotham
Journal:  J Nat Med       Date:  2018-02-27       Impact factor: 2.343

8.  MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality.

Authors:  Laura Gramantieri; Francesca Fornari; Manuela Ferracin; Angelo Veronese; Silvia Sabbioni; George Adrian Calin; Gian Luca Grazi; Carlo Maria Croce; Luigi Bolondi; Massimo Negrini
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

Review 9.  Dysregulation of apoptosis in hepatocellular carcinoma cells.

Authors:  Isabel Fabregat
Journal:  World J Gastroenterol       Date:  2009-02-07       Impact factor: 5.742

Review 10.  Cell death and cell death responses in liver disease: mechanisms and clinical relevance.

Authors:  Tom Luedde; Neil Kaplowitz; Robert F Schwabe
Journal:  Gastroenterology       Date:  2014-07-18       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.